Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases

Reuters03-28
<a href="https://laohu8.com/S/SMMT">Summit</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases
  • Summit Therapeutics published a medical research presentation on intracranial efficacy of ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after progression on a third-generation EGFR-TKI.
  • The document describes HARMONi as a global, randomized, double-blind phase 3 trial comparing ivonescimab plus pemetrexed and carboplatin with placebo plus the same chemotherapy in 438 patients.
  • In a prespecified exploratory analysis, median intracranial PFS in patients with baseline brain metastases was 10.1 months with ivonescimab plus chemotherapy versus 6.5 months with placebo plus chemotherapy.
  • For patients without baseline brain metastases, median intracranial PFS was 15.7 months with ivonescimab plus chemotherapy versus 11.6 months with placebo plus chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment